Results 11 to 20 of about 29,485 (291)
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer [PDF]
Frontiers in Immunology, 2023 The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity. Here,
Emilia Rabia +24 more
doaj +2 more sources
In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells
Antibodies, 2013 Engineered Fc-lacking bispecific antibodies have shown an exceptionally high potency for recruiting lymphocyte effector cells and enhancing antitumor activity, which is under evaluation in several clinical trials.
Luis Alvarez-Vallina +3 more
doaj +2 more sources
Bispecific antibodies in cancer immunotherapy
Therapeutic Advances in Vaccines and Immunotherapy, 2018 Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and ...
Eva Dahlén +2 more
doaj +2 more sources
Drug Discovery Today, 2015 Bispecific antibodies have emerged as molecules with a multitude of ...
Kontermann, Roland E., Brinkmann, Ulrich
openaire +4 more sources
Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
Antibodies, 2015 As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies ...
Joanie Del Bano +3 more
doaj +2 more sources
Intein mediated high throughput screening for bispecific antibodies [PDF]
mAbs, 2020 Bispecific antibodies comprise extremely diverse architectures enabling complex modes of action, such as effector cell recruitment or conditional target modulation via dual targeting, not conveyed by monospecific antibodies.
Tim Hofmann +8 more
doaj +2 more sources
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
International Journal of Nanomedicine, 2018 Haitao Pan,1,2 Jiayu Liu,1,2 Wentong Deng,1,2 Jieyu Xing,1,2 Qing Li,1,2 Zhong Wang1,2 1School of Pharmaceutical Sciences, 2Centre for Cellular & Structural Biology, Sun Yat-Sen University, Guangzhou, People’s Republic of China Introduction ...
Pan H +5 more
doaj +1 more source
Bispecific brain-penetrant antibodies for treatment of Alzheimer’s disease
The Journal of Prevention of Alzheimer's DiseaseThe emerging class of bispecific antibodies represents a significant advancement in Alzheimer’s disease (AD) immunotherapy by addressing the limited brain concentrations achieved with conventional monoclonal antibodies.
Dag Sehlin +8 more
doaj +2 more sources
[Bispecific antibodies: what future?].
Medecine sciences : M/S, 2009 Monoclonal antibodies have emerged as a very successful class of therapeutic agents. In their native format, monoclonal antibodies are monospecific in that they recognize only one epitope, but their Fc domain also binds to FcfR-expressing cells. Attempts to improve the cytotoxicity of antibodies, particularly in the cancer field, have led to the design
Pèlegrin, André, Robert, Bruno
openaire +4 more sources
iScienceSummary: A current challenge is the emergence of SARS-CoV-2 variants, such as BQ.1.1 and XBB.1.5, that can evade immune defenses, thereby limiting antibody drug effectiveness. Emergency-use antibody drugs, including the widely effective bebtelovimab, are
Tetsuya Inoue +12 more
doaj +2 more sources